Stock Analysts’ new coverage for Wednesday, September 6th:

Mizuho initiated coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI). Mizuho issued a buy rating on the stock.

Mizuho initiated coverage on shares of Achaogen (NASDAQ:AKAO). They issued a buy rating on the stock.

Mizuho began coverage on shares of Alder BioPharmaceuticals (NASDAQ:ALDR). They issued a buy rating on the stock.

Barclays PLC started coverage on shares of AveXis (NASDAQ:AVXS). They issued an overweight rating on the stock.

BMO Capital Markets assumed coverage on shares of Astrazeneca PLC (NYSE:AZN). They issued an outperform rating on the stock.

Barclays PLC began coverage on shares of bluebird bio (NASDAQ:BLUE). They issued an overweight rating on the stock.

DA Davidson initiated coverage on shares of Etsy (NASDAQ:ETSY). They issued a buy rating on the stock.

Mizuho assumed coverage on shares of NovoCure Limited (NASDAQ:NVCR). Mizuho issued a buy rating on the stock.

DA Davidson initiated coverage on shares of Overstock.com (NASDAQ:OSTK). They issued a buy rating on the stock.

UBS AG assumed coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX). They issued a market perform rating on the stock.

DA Davidson began coverage on shares of Park City Group (NASDAQ:PCYG). They issued a buy rating on the stock.

DA Davidson initiated coverage on shares of Shopify (NYSE:SHOP) (TSE:SH). DA Davidson issued a neutral rating on the stock.

Mizuho initiated coverage on shares of ViewRay (NASDAQ:VRAY). The firm issued a buy rating on the stock.

Mizuho initiated coverage on shares of Zogenix (NASDAQ:ZGNX). The firm issued a buy rating and a $28.00 price target on the stock. The analysts wrote, “We are initiating coverage on ZGNX with a BUY rating/$28 PT given our view of strong efficacy of its lead drug, ZX008, on Dravet patients. While investors are mainly concerned over competition from peers like GW Pharma, our analysis of the clinical data suggests that ZX008 may boast a superior long- term efficacy profile over its competitors with tolerable side effects. Upcoming Phase III read-outs in 3Q17 and 4Q17 or 1Q18 are critical to the company’s success; we have high conviction for positive outcomes. KeyPoints ZX008 is targeting a patient population with high unmet need and we believe it has a profile potentially better than key competition.””

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.